SPIA
AQST icon

Steward Partners Investment Advisory’s Aquestive Therapeutics AQST Stock Holding History

Steward Partners Investment Advisory’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.08K Buy
260
+10
+4% +$42 ﹤0.01% 4365
2026
Q1 		$1.04K Buy
+250
New +$1.01K ﹤0.01% 4182
2025
Q4 		– Sell
-2,500
Closed -$14K – 4315
2025
Q3 		$14K Buy
+2,500
New +$10.8K ﹤0.01% 3250

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Steward Partners Investment Advisory's AQST Position: Q2 2026 in Review

Steward Partners Investment Advisory increased its Aquestive Therapeutics (AQST) stake by 4% in Q2 2026, buying an estimated $42 and bringing the position to 260 shares worth $1.08K. The position accounts for ﹤0.01% of the portfolio, ranked #4365.

Steward Partners Investment Advisory first reported a position in AQST in Q3 2025 and has held it in 3 quarters since. The position peaked at $14K in Q3 2025. 173 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Steward Partners Investment Advisory held 260 shares of Aquestive Therapeutics worth $1.08K as of Q2 2026.
  • Steward Partners Investment Advisory bought 10 Aquestive Therapeutics shares in Q2 2026, an estimated $42.
  • Aquestive Therapeutics made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q2 2026, its #4365 holding.
  • Steward Partners Investment Advisory first reported a position in Aquestive Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Steward Partners Investment Advisory's Aquestive Therapeutics position peaked at $14K in Q3 2025.
  • 173 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.